ZA200407944B - Heteroaryl compounds which inhibit leukocyte adhesion mediated by Alpha-4 integrins - Google Patents
Heteroaryl compounds which inhibit leukocyte adhesion mediated by Alpha-4 integrins Download PDFInfo
- Publication number
- ZA200407944B ZA200407944B ZA200407944A ZA200407944A ZA200407944B ZA 200407944 B ZA200407944 B ZA 200407944B ZA 200407944 A ZA200407944 A ZA 200407944A ZA 200407944 A ZA200407944 A ZA 200407944A ZA 200407944 B ZA200407944 B ZA 200407944B
- Authority
- ZA
- South Africa
- Prior art keywords
- diethylamino
- ylamino
- pyrimidin
- dimethylcarbamoyloxyphenyl
- propionic acid
- Prior art date
Links
- 108010044426 integrins Proteins 0.000 title claims abstract description 35
- 102000006495 integrins Human genes 0.000 title claims abstract description 35
- 230000001404 mediated effect Effects 0.000 title claims abstract description 23
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 title abstract description 9
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 69
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 44
- 201000010099 disease Diseases 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- -1 4-fluorobenzenesulfonyl Chemical group 0.000 claims description 29
- 235000019260 propionic acid Nutrition 0.000 claims description 22
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 13
- 125000001153 fluoro group Chemical group F* 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 7
- 125000001246 bromo group Chemical group Br* 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- UEHGISKTKRLKLO-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(2,4-difluorophenyl)sulfonyl-prop-2-ynylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1N(CC#C)S(=O)(=O)C1=CC=C(F)C=C1F UEHGISKTKRLKLO-UHFFFAOYSA-N 0.000 claims description 2
- QNBPSKYQBURTTK-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(2-fluorophenyl)sulfonylmethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=CC=CC=C1F QNBPSKYQBURTTK-UHFFFAOYSA-N 0.000 claims description 2
- XGZSKLPECGWKPZ-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(3,4-difluorophenyl)sulfonyl-propan-2-ylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1N(C(C)C)S(=O)(=O)C1=CC=C(F)C(F)=C1 XGZSKLPECGWKPZ-UHFFFAOYSA-N 0.000 claims description 2
- QKAALEADKHAZAF-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(3,4-difluorophenyl)sulfonylmethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=CC=C(F)C(F)=C1 QKAALEADKHAZAF-UHFFFAOYSA-N 0.000 claims description 2
- PFFXAHQMJBDKHJ-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(3-fluorophenyl)sulfonylmethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=CC=CC(F)=C1 PFFXAHQMJBDKHJ-UHFFFAOYSA-N 0.000 claims description 2
- JODSWHRKWYEUDL-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(4-fluorophenyl)sulfonyl-prop-2-ynylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1N(CC#C)S(=O)(=O)C1=CC=C(F)C=C1 JODSWHRKWYEUDL-UHFFFAOYSA-N 0.000 claims description 2
- PQYHPONWVXTFQW-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[2-(2,4-difluorophenyl)sulfonylethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCCS(=O)(=O)C1=CC=C(F)C=C1F PQYHPONWVXTFQW-UHFFFAOYSA-N 0.000 claims description 2
- KBVXEABVOVICFP-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[2-(3,4-difluorophenyl)sulfonylethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCCS(=O)(=O)C1=CC=C(F)C(F)=C1 KBVXEABVOVICFP-UHFFFAOYSA-N 0.000 claims description 2
- KGSLYLUBNSUZQN-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[2-(4-fluorophenyl)sulfonylethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCCS(=O)(=O)C1=CC=C(F)C=C1 KGSLYLUBNSUZQN-UHFFFAOYSA-N 0.000 claims description 2
- BMCDGJILQKTGDV-UHFFFAOYSA-N 2-[[5-[(3,4-dichlorophenyl)sulfonylmethylamino]-2-(diethylamino)pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=CC=C(Cl)C(Cl)=C1 BMCDGJILQKTGDV-UHFFFAOYSA-N 0.000 claims description 2
- MAZNQIVGHXAJRX-UHFFFAOYSA-N 2-[[5-[2-(3,5-dichlorophenyl)sulfonylethylamino]-2-(diethylamino)pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCCS(=O)(=O)C1=CC(Cl)=CC(Cl)=C1 MAZNQIVGHXAJRX-UHFFFAOYSA-N 0.000 claims description 2
- QBKUKQMAGFTCQA-UHFFFAOYSA-N 2-[[5-[2-(4-chlorophenyl)sulfonylethylamino]-2-(diethylamino)pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCCS(=O)(=O)C1=CC=C(Cl)C=C1 QBKUKQMAGFTCQA-UHFFFAOYSA-N 0.000 claims description 2
- IKXAHYJACJXEFL-UHFFFAOYSA-N 2-[[5-[butyl-(4-fluorophenyl)sulfonylamino]-2-(diethylamino)pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(CCCC)C1=CN=C(N(CC)CC)N=C1NC(C(O)=O)CC1=CC=C(OC(=O)N(C)C)C=C1 IKXAHYJACJXEFL-UHFFFAOYSA-N 0.000 claims description 2
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 claims description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- YQPPFPAOQXSSBY-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(2,4-difluorophenyl)sulfonylmethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=CC=C(F)C=C1F YQPPFPAOQXSSBY-UHFFFAOYSA-N 0.000 claims 1
- NADHCGMMZGXNJU-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(3,5-difluorophenyl)sulfonylmethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=CC(F)=CC(F)=C1 NADHCGMMZGXNJU-UHFFFAOYSA-N 0.000 claims 1
- RAPVDKCWUQBKGG-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1N(C(C)C)S(=O)(=O)C1=CC=C(F)C=C1 RAPVDKCWUQBKGG-UHFFFAOYSA-N 0.000 claims 1
- FQXLXEDBFFIHNX-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[2-(3,5-difluorophenyl)sulfonylethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCCS(=O)(=O)C1=CC(F)=CC(F)=C1 FQXLXEDBFFIHNX-UHFFFAOYSA-N 0.000 claims 1
- XCPNGIQSOZEOOZ-UHFFFAOYSA-N 2-[[5-(benzenesulfonylmethylamino)-2-(diethylamino)pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=CC=CC=C1 XCPNGIQSOZEOOZ-UHFFFAOYSA-N 0.000 claims 1
- FPIRQHBDFYJJDM-UHFFFAOYSA-N 2-[[5-[(3,5-dichlorophenyl)sulfonylmethylamino]-2-(diethylamino)pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=CC(Cl)=CC(Cl)=C1 FPIRQHBDFYJJDM-UHFFFAOYSA-N 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract description 16
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 201000006417 multiple sclerosis Diseases 0.000 abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 208000030507 AIDS Diseases 0.000 abstract description 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 4
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 4
- 206010012289 Dementia Diseases 0.000 abstract description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract description 4
- 206010027476 Metastases Diseases 0.000 abstract description 4
- 208000006673 asthma Diseases 0.000 abstract description 4
- 230000002757 inflammatory effect Effects 0.000 abstract description 4
- 230000009401 metastasis Effects 0.000 abstract description 4
- 238000002054 transplantation Methods 0.000 abstract description 4
- 208000014644 Brain disease Diseases 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 45
- 239000004480 active ingredient Substances 0.000 description 25
- 238000009472 formulation Methods 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 12
- 210000000265 leukocyte Anatomy 0.000 description 12
- 239000003826 tablet Substances 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 239000008107 starch Substances 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 102000000844 Cell Surface Receptors Human genes 0.000 description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 201000009906 Meningitis Diseases 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000004852 Lung Injury Diseases 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- 206010038910 Retinitis Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 206010069363 Traumatic lung injury Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 231100000515 lung injury Toxicity 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000010062 adhesion mechanism Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008387 emulsifying waxe Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- IKHARSQFGRMOKN-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[(2,6-difluorophenyl)sulfonylmethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCS(=O)(=O)C1=C(F)C=CC=C1F IKHARSQFGRMOKN-UHFFFAOYSA-N 0.000 description 1
- AIGZEIASVOBQCI-UHFFFAOYSA-N 2-[[2-(diethylamino)-5-[2-(2,3-difluorophenyl)sulfonylethylamino]pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1NCCS(=O)(=O)C1=CC=CC(F)=C1F AIGZEIASVOBQCI-UHFFFAOYSA-N 0.000 description 1
- BBTTXCPSXDESDD-UHFFFAOYSA-N 2-[[5-[(4-chlorophenyl)sulfonyl-propan-2-ylamino]-2-(diethylamino)pyrimidin-4-yl]amino]-3-[4-(dimethylcarbamoyloxy)phenyl]propanoic acid Chemical compound C=1C=C(OC(=O)N(C)C)C=CC=1CC(C(O)=O)NC1=NC(N(CC)CC)=NC=C1N(C(C)C)S(=O)(=O)C1=CC=C(Cl)C=C1 BBTTXCPSXDESDD-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010002921 Aortitis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010019759 Hepatitis chronic persistent Diseases 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000005005 aminopyrimidines Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38324402P | 2002-05-24 | 2002-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200407944B true ZA200407944B (en) | 2006-07-26 |
Family
ID=29584533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200407944A ZA200407944B (en) | 2002-05-24 | 2004-10-01 | Heteroaryl compounds which inhibit leukocyte adhesion mediated by Alpha-4 integrins |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7335663B2 (enExample) |
| EP (1) | EP1507533B1 (enExample) |
| JP (1) | JP4413135B2 (enExample) |
| CN (1) | CN1311829C (enExample) |
| AT (1) | ATE464298T1 (enExample) |
| AU (1) | AU2003237302B8 (enExample) |
| BR (1) | BR0309619A (enExample) |
| CA (1) | CA2480756A1 (enExample) |
| DE (1) | DE60332109D1 (enExample) |
| EA (1) | EA008180B1 (enExample) |
| IL (1) | IL164323A (enExample) |
| MX (1) | MXPA04011657A (enExample) |
| NO (1) | NO20045276L (enExample) |
| NZ (1) | NZ535723A (enExample) |
| TW (1) | TW200307671A (enExample) |
| WO (1) | WO2003099231A2 (enExample) |
| ZA (1) | ZA200407944B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1045157A1 (zh) * | 1999-01-22 | 2002-11-15 | 依兰制药公司 | 抑制vla-4介导的白细胞粘着的化合物 |
| US20050074451A1 (en) * | 2003-06-25 | 2005-04-07 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating rheumatoid arthritis |
| JP2007528397A (ja) * | 2004-03-10 | 2007-10-11 | メルク エンド カムパニー インコーポレーテッド | Ｖｌａ−４アンタゴニスト |
| CA2573245C (en) * | 2004-07-08 | 2013-10-01 | Elan Pharmaceuticals, Inc. | Multivalent vla-4 antagonists comprising polymer moieties |
| WO2006023396A2 (en) * | 2004-08-16 | 2006-03-02 | Merck & Co., Inc. | Vla-4 antagonists |
| ZA200803016B (en) * | 2005-09-29 | 2009-10-28 | Elan Pharmaceuticals Inc Wyeth | Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| ATE493405T1 (de) * | 2005-09-29 | 2011-01-15 | Elan Pharm Inc | Pyrimidinylamidverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren |
| EA017110B1 (ru) * | 2006-02-27 | 2012-09-28 | Элан Фамэсьютикэлс, Инк. | ПИРИМИДИНИЛСУЛЬФОНАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ ПИРИМИДИНИЛСУЛЬФОНАМИДНЫХ СОЕДИНЕНИЙ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО ИНТЕГРИНОМ α4, СПОСОБ СНИЖЕНИЯ И/ИЛИ ПРЕДУПРЕЖДЕНИЯ ВОСПАЛИТЕЛЬНОГО КОМПОНЕНТА ЗАБОЛЕВАНИЯ ИЛИ АУТОИММУННОГО ОТВЕТА |
| US8410115B2 (en) * | 2006-02-28 | 2013-04-02 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
| HUE047230T2 (hu) | 2006-02-28 | 2020-04-28 | Biogen Ma Inc | Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei |
| KR20080104343A (ko) * | 2006-03-03 | 2008-12-02 | 엘란 파마슈티칼스, 인크. | 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법 |
| CA2708262A1 (en) * | 2007-12-07 | 2009-06-18 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating liquid tumors |
| SG10201401836RA (en) * | 2009-04-27 | 2014-10-30 | Elan Pharm Inc | Pyridinone antagonists of alpha-4 integrins |
| BR112012017014B1 (pt) | 2010-01-11 | 2021-07-20 | Biogen Ma Inc | Métodos para detecção de anticorpos de vírus jc |
| US11287423B2 (en) | 2010-01-11 | 2022-03-29 | Biogen Ma Inc. | Assay for JC virus antibodies |
| US8343706B2 (en) | 2010-01-25 | 2013-01-01 | International Business Machines Corporation | Fluorine-free fused ring heteroaromatic photoacid generators and resist compositions containing the same |
| HUE061244T2 (hu) | 2011-05-31 | 2023-06-28 | Biogen Ma Inc | A PML kockázat értékelésének módszere |
| EP3004334A4 (en) | 2013-05-28 | 2016-12-21 | Biogen Ma Inc | METHOD FOR ASSESSING A PML RISK |
| EP3810085A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| ES2987796T3 (es) | 2018-10-30 | 2024-11-18 | Gilead Sciences Inc | Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias |
| DK3873884T3 (da) | 2018-10-30 | 2025-02-17 | Gilead Sciences Inc | 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme |
| WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| WO2020092401A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
| CN111197057B (zh) * | 2018-11-19 | 2024-04-19 | 中国科学院分子细胞科学卓越创新中心 | 调控免疫细胞迁移的组合物和方法 |
| AU2020329207B2 (en) | 2019-08-14 | 2024-02-29 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2525656A1 (de) | 1974-06-19 | 1976-01-15 | Sandoz Ag | Verfahren zur herstellung neuer heterocyclischer verbindungen |
| US4046876A (en) * | 1974-11-08 | 1977-09-06 | Mitsubishi Chemical Industries Limited | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
| US4096255A (en) * | 1974-11-08 | 1978-06-20 | Mitsubishi Chemical Industries Limited | N2 -naphthalenesulfonyl-L-argininamides, and pharmaceutical salts, compositions and methods |
| US4073914A (en) * | 1974-11-08 | 1978-02-14 | Mitsubishi Chemical Industries Limited | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
| US4055651A (en) * | 1974-11-08 | 1977-10-25 | Mitsubishi Chemical Industries Ltd. | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
| US4041156A (en) * | 1974-11-08 | 1977-08-09 | Mitsubishi Chemical Industries Limited | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
| US4018915A (en) * | 1976-01-05 | 1977-04-19 | Mitsubishi Chemical Industries Ltd. | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
| US4070457A (en) * | 1974-11-08 | 1978-01-24 | Mitsubishi Chemical Industries Ltd. | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
| US4055636A (en) * | 1974-11-08 | 1977-10-25 | Mitsubishi Chemical Industries Ltd. | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
| US4104392A (en) * | 1974-11-08 | 1978-08-01 | Mitsubishi Chemical Industries Ltd. | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them |
| JPS5727454B2 (enExample) * | 1975-02-21 | 1982-06-10 | ||
| CA1102316A (en) | 1975-12-09 | 1981-06-02 | Shosuke Okamoto | N su2 xx-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof |
| US4036955A (en) * | 1976-07-22 | 1977-07-19 | Mitsubishi Chemical Industries Ltd. | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
| US4018913A (en) * | 1976-01-14 | 1977-04-19 | Mitsubishi Chemical Industries Ltd. | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
| DE2742173A1 (de) * | 1977-09-20 | 1979-03-29 | Bayer Ag | Phenoxy-pyridinyl(pyrimidinyl)-alkanole, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide |
| US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| IT1211096B (it) * | 1981-08-20 | 1989-09-29 | Lpb Ist Farm | Pirimidine e s.triazinici adattivita' ipolipidemizzante. |
| US4672065A (en) * | 1982-11-19 | 1987-06-09 | Chevron Research Company | N-substituted phenoxyacetamide fungicides |
| US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4565814A (en) | 1983-01-28 | 1986-01-21 | Sanofi | Pyridazine derivatives having a psychotropic action and compositions |
| JPS59212480A (ja) | 1983-05-17 | 1984-12-01 | Nippon Soda Co Ltd | ピリダジン誘導体及び除草剤 |
| DE3322720A1 (de) * | 1983-06-24 | 1985-01-03 | Chemische Werke Hüls AG, 4370 Marl | Verwendung von in 2-stellung mit (substituierten) aminogruppen substituierten 4-dl-alkylester-(alpha)-alaninyl-6-chlor-s-triazinen als herbizide, insbesondere gegen flughafer |
| US4505910A (en) * | 1983-06-30 | 1985-03-19 | American Home Products Corporation | Amino-pyrimidine derivatives, compositions and use |
| NZ210669A (en) | 1983-12-27 | 1988-05-30 | Syntex Inc | Benzoxazin-4-one derivatives and pharmaceutical compositions |
| PH22520A (en) * | 1984-11-12 | 1988-10-17 | Yamanouchi Pharma Co Ltd | Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them |
| US4959364A (en) * | 1985-02-04 | 1990-09-25 | G. D. Searle & Co. | Method of treating inflammation, allergy, asthma and proliferative skin disease using heterocyclic amides |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JPH0784424B2 (ja) | 1987-04-15 | 1995-09-13 | 味の素株式会社 | チロシン誘導体及びその用途 |
| EP0330506A3 (en) | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | Vla proteins |
| DE3904931A1 (de) * | 1989-02-17 | 1990-08-23 | Bayer Ag | Pyridyl-substituierte acrylsaeureester |
| US5030644A (en) * | 1989-07-31 | 1991-07-09 | Merck & Co., Inc. | Imidazole compounds and their use as transglutaminase inhibitors |
| US5260210A (en) | 1989-09-27 | 1993-11-09 | Rubin Lee L | Blood-brain barrier model |
| US4992439A (en) * | 1990-02-13 | 1991-02-12 | Bristol-Myers Squibb Company | Pyridazine carboxylic acids and esters |
| FR2679903B1 (fr) | 1991-08-02 | 1993-12-03 | Elf Sanofi | Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant. |
| NZ239846A (en) * | 1990-09-27 | 1994-11-25 | Merck & Co Inc | Sulphonamide derivatives and pharmaceutical compositions thereof |
| DE4108029A1 (de) * | 1991-03-13 | 1992-09-17 | Bayer Ag | Triazinyl-substituierte acrylsaeureester |
| WO1992016549A1 (de) | 1991-03-18 | 1992-10-01 | Pentapharm Ag | Para-substituierte phenylalanin-derivate |
| IT1247509B (it) * | 1991-04-19 | 1994-12-17 | Univ Cagliari | Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus |
| US5296486A (en) | 1991-09-24 | 1994-03-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Leukotriene biosynthesis inhibitors |
| AU3420693A (en) | 1991-12-24 | 1993-07-28 | Fred Hutchinson Cancer Research Center | Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv |
| BR9306058A (pt) * | 1992-03-11 | 1997-11-18 | Narhex Ltd | Derivados de amina de hidrocarbonetos oxo- e hidroxi- substituidos |
| DE4227748A1 (de) * | 1992-08-21 | 1994-02-24 | Bayer Ag | Pyridyloxy-acrylsäureester |
| JP2848232B2 (ja) * | 1993-02-19 | 1999-01-20 | 武田薬品工業株式会社 | アルデヒド誘導体 |
| US5770573A (en) * | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| US5510332A (en) * | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
| EP0769958B1 (en) | 1994-07-11 | 2003-04-16 | Athena Neurosciences, Inc. | Inhibitors of leukocyte adhesion |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| IL117659A (en) | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
| MX9801716A (es) * | 1995-08-30 | 1998-05-31 | Searle & Co | Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina. |
| PT765879E (pt) * | 1995-09-29 | 2001-05-31 | Sankyo Co | Derivados 13-substituidos de milbemicina-5-oxima sua preparacao e utilizacao contra insectos e outras pragas |
| DE19536891A1 (de) | 1995-10-04 | 1997-04-10 | Basf Ag | Neue Aminosäurederivate, ihre Herstellung und Verwendung |
| DE19548709A1 (de) | 1995-12-23 | 1997-07-03 | Merck Patent Gmbh | Tyrosinderivate |
| US6211333B1 (en) | 1996-06-21 | 2001-04-03 | Takeda Chemical Industries, Ltd. | Method for producing peptides and their salts which have an agonist activity of luteinizing hormone releasing hormones secreted from the hypothalamus |
| EP0907637A1 (de) | 1996-06-28 | 1999-04-14 | MERCK PATENT GmbH | Phenylalanin-derivate als integrin-inhibitoren |
| DE19629817A1 (de) * | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| DE19647317A1 (de) * | 1996-11-15 | 1998-05-20 | Hoechst Schering Agrevo Gmbh | Substituierte Stickstoff-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
| DE19647381A1 (de) * | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| NZ334950A (en) | 1996-11-22 | 2001-03-30 | Lilly Co Eli | N-(aryl/heteroarylacetyl) amino acid esters and pharmaceutical compositions comprising same; useful for inhibiting beta-amyloid peptide release and/or its synthesis |
| AU6264898A (en) | 1997-02-04 | 1998-08-25 | Versicor Inc | Solid phase and combinatorial library syntheses of 3,1-benzoxazine-4-ones |
| DE19713000A1 (de) | 1997-03-27 | 1998-10-01 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| EP1001764A4 (en) | 1997-05-29 | 2005-08-24 | Merck & Co Inc | HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION |
| ATE318841T1 (de) | 1997-05-29 | 2006-03-15 | Merck & Co Inc | Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren |
| IL133640A0 (en) | 1997-07-31 | 2001-04-30 | Elan Pharm Inc | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| IL133641A0 (en) | 1997-07-31 | 2001-04-30 | Elan Pharm Inc | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| AR016133A1 (es) | 1997-07-31 | 2001-06-20 | Wyeth Corp | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
| PL338373A1 (en) | 1997-07-31 | 2000-10-23 | Elan Pharm Inc | Dipeptide and its affinite compounds inhibiting adhesion of leucocytes occurring through mediation of vla-4 |
| ATE260243T1 (de) | 1997-08-22 | 2004-03-15 | Hoffmann La Roche | N-aroylphenylalaninderivate |
| KR100554815B1 (ko) | 1997-08-22 | 2006-02-22 | 에프. 호프만-라 로슈 아게 | 엔-아로일페닐알라닌 유도체 |
| CN1294576A (zh) | 1998-01-23 | 2001-05-09 | 诺瓦提斯公司 | Vla－4拮抗剂 |
| US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
| KR20010042614A (ko) | 1998-04-10 | 2001-05-25 | 윌리암스 로저 에이 | 비트로넥틴 길항제로서 복소환식 글리실 베타-알라닌 유도체 |
| HUP0101419A3 (en) | 1998-04-16 | 2002-08-28 | Texas Biotechnology Corp Houst | Compounds that inhibit the binding of integrins to their receptors and pharmaceutical compositions containing them |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9825652D0 (en) | 1998-11-23 | 1999-01-13 | Celltech Therapeutics Ltd | Chemical compounds |
| HK1045157A1 (zh) * | 1999-01-22 | 2002-11-15 | 依兰制药公司 | 抑制vla-4介导的白细胞粘着的化合物 |
| WO2000043369A1 (en) | 1999-01-22 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
-
2003
- 2003-05-26 TW TW092114184A patent/TW200307671A/zh unknown
- 2003-05-27 NZ NZ535723A patent/NZ535723A/en unknown
- 2003-05-27 CA CA002480756A patent/CA2480756A1/en not_active Abandoned
- 2003-05-27 DE DE60332109T patent/DE60332109D1/de not_active Expired - Lifetime
- 2003-05-27 AT AT03736768T patent/ATE464298T1/de not_active IP Right Cessation
- 2003-05-27 BR BR0309619-0A patent/BR0309619A/pt not_active IP Right Cessation
- 2003-05-27 AU AU2003237302A patent/AU2003237302B8/en not_active Ceased
- 2003-05-27 MX MXPA04011657A patent/MXPA04011657A/es active IP Right Grant
- 2003-05-27 EP EP03736768A patent/EP1507533B1/en not_active Expired - Lifetime
- 2003-05-27 US US10/494,788 patent/US7335663B2/en not_active Expired - Fee Related
- 2003-05-27 JP JP2004506758A patent/JP4413135B2/ja not_active Expired - Fee Related
- 2003-05-27 CN CNB038112582A patent/CN1311829C/zh not_active Expired - Fee Related
- 2003-05-27 US US10/447,208 patent/US7008949B2/en not_active Expired - Fee Related
- 2003-05-27 WO PCT/US2003/017150 patent/WO2003099231A2/en not_active Ceased
- 2003-05-27 EA EA200401561A patent/EA008180B1/ru not_active IP Right Cessation
-
2004
- 2004-09-28 IL IL164323A patent/IL164323A/en not_active IP Right Cessation
- 2004-10-01 ZA ZA200407944A patent/ZA200407944B/en unknown
- 2004-12-01 NO NO20045276A patent/NO20045276L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20050130999A1 (en) | 2005-06-16 |
| EP1507533A4 (en) | 2007-05-23 |
| EA200401561A1 (ru) | 2005-06-30 |
| AU2003237302B8 (en) | 2008-04-03 |
| IL164323A0 (en) | 2005-12-18 |
| TW200307671A (en) | 2003-12-16 |
| US20040142954A1 (en) | 2004-07-22 |
| AU2003237302A1 (en) | 2003-12-12 |
| CN1652789A (zh) | 2005-08-10 |
| AU2003237302B2 (en) | 2008-03-06 |
| EP1507533B1 (en) | 2010-04-14 |
| CN1311829C (zh) | 2007-04-25 |
| CA2480756A1 (en) | 2003-12-04 |
| US7008949B2 (en) | 2006-03-07 |
| MXPA04011657A (es) | 2005-08-18 |
| IL164323A (en) | 2010-02-17 |
| EA008180B1 (ru) | 2007-04-27 |
| BR0309619A (pt) | 2005-06-28 |
| NO20045276L (no) | 2004-12-01 |
| WO2003099231A3 (en) | 2004-01-22 |
| JP2005529155A (ja) | 2005-09-29 |
| DE60332109D1 (de) | 2010-05-27 |
| EP1507533A2 (en) | 2005-02-23 |
| JP4413135B2 (ja) | 2010-02-10 |
| ATE464298T1 (de) | 2010-04-15 |
| NZ535723A (en) | 2005-08-26 |
| US7335663B2 (en) | 2008-02-26 |
| WO2003099231A2 (en) | 2003-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200407590B (en) | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha-4 intergrins | |
| JP3087763B2 (ja) | 新規な複素環式化合物およびそれを含有する医薬組成物 | |
| DE69637040T2 (de) | Derivate monocyclischer Polyamine, ihre Herstellung und ihre Verwendung als antivirale Mittel | |
| WO2025049402A1 (en) | Kras modulators and uses thereof | |
| DE69629156T2 (de) | Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel | |
| US7335663B2 (en) | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α4 integrins | |
| WO2009017838A2 (en) | Combinations of jak-2 inhibitors and other agents | |
| CA2568832A1 (en) | Indole derivatives as antiviral agents | |
| FI120403B (fi) | 4-(2-amino-6-(syklopropyyliamino)-9H-purin-9-yyli)-2-syklopenteeni-1-metanoli-sukkinaatti viruksia torjuvana aineena | |
| WO2017202311A1 (zh) | 一种2-氨基嘧啶类化合物的多晶型形式 | |
| CN102060722B (zh) | 一种含砷化合物及其制备方法和用途 | |
| WO2022058785A1 (en) | Olaparib oxalic acid cocrystals and their pharmaceutical use | |
| CN101235013A (zh) | 结晶型1-（3-氟苯基）-5-甲基-2-（1h）吡啶酮、其制备方法、及其组合物和应用 | |
| JPH0532635A (ja) | ヒスタミン誘導体の治療への応用と、新規なヒスタミン誘導体と、この誘導体の医薬としての使用 | |
| CN112939896B (zh) | 一种双季铵化合物及其制备方法和用途 | |
| JPS62919B2 (enExample) | ||
| JPS6223723B2 (enExample) | ||
| JPS6130520A (ja) | 抗腫瘍剤 | |
| HK1072608B (en) | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins | |
| WO2015109925A1 (zh) | 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途 | |
| JPWO2001012198A1 (ja) | 心筋梗塞治療薬 |